Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy
Clinical trial NCT04816214 · TERMINATED
Trial details
- NCT number
- NCT04816214
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-22
- Primary completion
- 2022-12-27
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.